We are live on ! Find out more
ARTL icon

Artelo Biosciences
ARTL

11 hedge funds and large institutions have $830K invested in Artelo Biosciences in 2026 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

588% more capital invested

Capital invested by funds: $121K → $830K (+$709K)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

38% more funds holding

Funds holding: 8 → 11 (+3)

4.69% more ownership

Funds ownership: 1.63% → 6.32% (+4.7%)

Holders
11
Holders Change
+3
Holders Change %
+37.5%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
2
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Kathmere Capital Management
Pennsylvania
+$62.7K
2
Jane Street
Jane Street
New York
+$61.9K
3
Citigroup
Citigroup
New York
+$14.5K
4
TRCT
Tower Research Capital (TRC)
New York
+$10.4K
5
AS
Altshuler Shaham
Israel
+$4.21K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$41K
2
Two Sigma Investments
Two Sigma Investments
New York
-$25.2K
3
VF
Virtu Financial
New York
-$21K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$13.9K
5
Bank of America
Bank of America
North Carolina
-$21
Name Holding Trade Value Shares
Change 		Change in
Stake
AS
1
Altshuler Shaham
Israel
$484K +$4.21K +889 New
KCM
2
Kathmere Capital Management
Pennsylvania
$100K +$62.7K +13,250 New
Jane Street
3
Jane Street
New York
$99.1K +$61.9K +13,079 New
VCM
4
Vanguard Capital Management
Pennsylvania
$76.8K +$47.9K +10,129 New
VFT
5
Vanguard Fiduciary Trust
Pennsylvania
$23.8K +$14.8K +3,139 New
Citigroup
6
Citigroup
New York
$23.3K +$14.5K +3,076 New
TRCT
7
Tower Research Capital (TRC)
New York
$21.4K +$10.4K +2,192 +346%
CS
8
Clear Street
New York
$758 +$473 +100 New
RIL
9
Rothschild Investment LLC
Illinois
$15 +$5 +1 +100%
Carson Wealth (CWM LLC)
10
Carson Wealth (CWM LLC)
Nebraska
$8 +$5 +1 New
Osaic Holdings
11
Osaic Holdings
Arizona
$7 +$5 +1 New
UBS Group
12
UBS Group
Switzerland
– -$41K -11,207 Closed
Two Sigma Investments
13
Two Sigma Investments
New York
– -$25.2K -6,890 Closed
VF
14
Virtu Financial
New York
– -$21K -5,622 Closed
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$13.9K -3,799 Closed
Bank of America
16
Bank of America
North Carolina
– -$21 -6 Closed

ARTL Hedge Fund Activity: Q1 2026 in Review

11 of the 8,143 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q1 2026, worth a combined $830K — up 588% from $121K a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ARTL positions and 5 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Kathmere Capital Management, opening a new position worth an estimated $62.7K. The largest seller was UBS Group, exiting entirely with an estimated $41K sold.

  • 11 institutional investors held Artelo Biosciences (ARTL) as of Q1 2026, up from 8 in Q4 2025.
  • Funds reported $830K of Artelo Biosciences stock for Q1 2026, up 588% quarter-over-quarter.
  • 9 funds opened new Artelo Biosciences positions in Q1 2026 and 5 closed out, a net change of +4 holders.
  • The largest Artelo Biosciences buyer in Q1 2026 was Kathmere Capital Management, an estimated $62.7K added.
  • The largest Artelo Biosciences seller in Q1 2026 was UBS Group, an estimated $41K sold.

Based on aggregated 13F filings for Q1 2026.